PMID- 34312684
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220224
IS  - 1432-1440 (Electronic)
IS  - 0946-2716 (Linking)
VI  - 99
IP  - 11
DP  - 2021 Nov
TI  - Lipid metabolism, inflammation, and foam cell formation in health and metabolic 
      disorders: targeting mTORC1.
PG  - 1497-1509
LID - 10.1007/s00109-021-02117-8 [doi]
AB  - Metabolic homeostasis is important for maintaining a healthy lifespan. Lipid 
      metabolism is particularly necessary for the maintenance of metabolic energy 
      sources and their storage, and the structure and function of cell membranes, as 
      well as for the regulation of nutrition through lipogenesis, lipolysis, and 
      lipophagy. Dysfunctional lipid metabolism leads to the development of metabolic 
      disorders, such as atherosclerosis, diabetes mellitus, and non-alcoholic fatty 
      liver disease (NAFLD). Furthermore, dyslipidaemia causes inflammatory responses 
      and foam cell formation. Mechanistic target of rapamycin (mTOR) signalling is a 
      key regulator of diverse cellular processes, including cell metabolism and cell 
      fate. mTOR complex 1 (mTORC1) is involved in lipid metabolism and immune 
      responses in the body. Therefore, the mTORC1 signalling pathway has been 
      suggested as a potential therapeutic target for the treatment of metabolic 
      disorders. In this review, we focus on the roles of mTORC1 in lipid metabolism 
      and inflammation, and present current evidence on its involvement in the 
      development and progression of metabolic disorders.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Cheon, So Yeong
AU  - Cheon SY
AD  - Department of Biotechnology, College of Biomedical & Health Science, Konkuk 
      University, Chungju, Republic of Korea.
FAU - Cho, KyoungJoo
AU  - Cho K
AUID- ORCID: 0000-0002-9478-4998
AD  - Department of Life Science, College of Science and Engineering, Kyonggi 
      University, Gwanggyosan-ro, Yeongtong-gu, Suwon, Gyeonggi-do, 16227, Republic of 
      Korea. kcho0611@kgu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210726
PL  - Germany
TA  - J Mol Med (Berl)
JT  - Journal of molecular medicine (Berlin, Germany)
JID - 9504370
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
SB  - IM
MH  - Animals
MH  - Foam Cells
MH  - Humans
MH  - Inflammation/drug therapy/*metabolism
MH  - *Lipid Metabolism
MH  - Mechanistic Target of Rapamycin Complex 1/antagonists & inhibitors/*metabolism
MH  - Metabolic Diseases/drug therapy/*metabolism
MH  - Signal Transduction
OTO - NOTNLM
OT  - Foam cells
OT  - Inflammation
OT  - Lipid metabolism
OT  - Mechanistic target of rapamycin (mTOR)
OT  - Metabolic disorders
EDAT- 2021/07/28 06:00
MHDA- 2022/02/25 06:00
CRDT- 2021/07/27 07:16
PHST- 2020/10/18 00:00 [received]
PHST- 2021/07/14 00:00 [accepted]
PHST- 2021/07/12 00:00 [revised]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/07/27 07:16 [entrez]
AID - 10.1007/s00109-021-02117-8 [pii]
AID - 10.1007/s00109-021-02117-8 [doi]
PST - ppublish
SO  - J Mol Med (Berl). 2021 Nov;99(11):1497-1509. doi: 10.1007/s00109-021-02117-8. 
      Epub 2021 Jul 26.